Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Veel nieuwe behandelopties verwacht bij behandeling urotheelcelcarcinoom
nov 2019 | Immuuntherapie, Uro-oncologie